We are joined by John Doupis at the ADA meeting in San Francisco to talk about cardiovascular outcome trials and the results of the highly anticipated REWIND trial, which were presented at this years’ conference.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
Questions:
1. What are the major challenges in designing cardiovascular outcome trials? (0:05)
2. How have the results of the diabetes cardiovascular outcome trials influenced the management of type 2 diabetes? (1:00)
3. How did the REWIND study design differ from other cardiovascular outcome trials? (1:51)
4. What can we expect from the results of the REWIND trial? (2:55)
5. What are your highlights of the ADA 2019 meeting so far? (4:09)
John Doupis is a clinical researcher, lecturer and on the advisory board for Eli Lilly, Novo Nordisk and AstraZeneca.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
